Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)

Vaishali Sanchorawala, Monique Minnema, Yvonne Efebera et al. Nov 03, 2025 pp. 691-691 10.1182/blood-2025-691

Abstract Introduction AL amyloidosis is a rare disorder caused by amyloid fibrils produced by clonal plasma cells, leadi...

Feasibility of collecting social determinants of health data in the frontline pediatric acute lymphoblastic leukemia (ALL) trial AALL1731: A report from the Children's oncology group

Haley Newman, Morgan Paul, John Kairalla et al. Nov 03, 2025 pp. 2742-2742 10.1182/blood-2025-2742

Abstract Background : Poverty-exposed children with B-acute lymphoblastic leukemia (B-ALL) are more likely to relapse, and long-term survivo...

Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent β-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE)

Jia Chen, Yongrong Lai, Xiaowen Zhai et al. Nov 03, 2025 pp. 6090-6090 10.1182/blood-2025-6090

Abstract Background: β-hemoglobinopathies, such as β-thalassemia and sickle cell disease (SCD), result from mutations in the β-globin gene (...

BET inhibition targets pathogenic interstitial macrophages to limit antibody mediated fibrosis in bronchiolitis obliterans chronic gvhd

Rathan Kumar, Lotus Neidemire-Colley, Elizabeth Garfinkle et al. Nov 03, 2025 pp. 5859-5859 10.1182/blood-2025-5859

Abstract Introduction: Chronic graft-versus-host disease (cGVHD) is a major cause of late mortality in allogeneic-hematopoietic stem cell tr...

Intra-sample flow cytometry analysis identifies upregulated interleukin-6 receptor (CD126) as a potential therapeutic target in gain(1q) myeloma

Rebecca Sarsam, Carolina Valensise, Mathilda Gibson-Watt et al. Nov 03, 2025 pp. 7486-7486 10.1182/blood-2025-7486

Abstract Introduction: Interleukin-6 (IL6) is a proliferative factor in multiple myeloma (MM) and important for plasma c...

Genetic analysis and clinical correlations in marginal zone lymphoma

Wei Wang, Hao Cai, Yan Zhang et al. Nov 03, 2025 pp. 1768-1768 10.1182/blood-2025-1768

Abstract Background: Marginal zone lymphoma (MZL) is a heterogeneous group of indolent B-cell malignancies with distinct molecular landscape...

Real-world effectiveness and safety of hydroxyurea in adults with hemoglobin SC disease: A retrospective cohort study in Quebec, Canada

Alice Girard, Laurianne Charette, Mélissa Haouchine et al. Nov 03, 2025 pp. 410-410 10.1182/blood-2025-410

Abstract Background Hemoglobin SC disease (HbSC) is the second most prevalent genotype of sickle cell disease (SCD) worl...

Innate immune lectins shape anti-blood group antibody development and transfusion outcomes

Shang-Chuen Wu, Connie Arthur, Hau-Ming Jan et al. Nov 03, 2025 pp. 544-544 10.1182/blood-2025-544

Abstract Introduction Anti-ABO(H) antibodies are the primary immunological barrier in both transfusion and transplantation. Although these a...

Bi-allelic TET2 alterations are frequently found in NPM1 mutated AML and constitute a distinct subgroup with unfavorable prognosis

Wencke Walter, Sarah Keppler, Veronika Ecker et al. Nov 03, 2025 pp. 339-339 10.1182/blood-2025-339

Abstract Background: Mutations (mut) in TET2 and NPM1 are common in myeloid neoplasms, with NPM1mut defining a distinct genetic entity in ac...

Tropomyosin 1 promotes platelet adhesion and clot contraction to inhibit thrombosis

Po-Lun Kung, Victor Tsao, Alina Peshkova et al. Nov 03, 2025 pp. 4871-4871 10.1182/blood-2025-4871

Abstract Background: Failures in thrombosis prevention and treatment demand novel therapeutic approaches. We hypothesized that novel genetic...

Impact of race and socioeconomics on access to T-cell engaging therapy in US patients with relapsed/refractory multiple myeloma (RRMM)

Yvonne Efebera, Yelak Biru, Jeff O'Donnell et al. Nov 03, 2025 pp. 2813-2813 10.1182/blood-2025-2813

Abstract Background People of color (POC) and patients (pts) from socioeconomically disadvantaged backgrounds often face financial, geograph...

Access to innovative treatment for paroxysmal nocturnal hemoglobinuria in low- and middle-income countries

Andrielle Yost, Mercedes Arteaga, Alicia Annamalay et al. Nov 03, 2025 pp. 4387-4387 10.1182/blood-2025-4387

Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, and life-threatening blood disorder characterized by unco...

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Ola Landgren, Russ Kuker, Ryan Reddy et al. Nov 03, 2025 pp. 4052-4052 10.1182/blood-2025-4052

Abstract Background Evaluation of multiple myeloma disease burden and response to therapy are currently suboptimal. For instance, ~30% of mye...

A deep dive into the bone marrow plasma proteome by optimized extracellular vesicle enrichment

Charlotte Hjort, Ole Østergaard, Hanne Vibeke Marquart et al. Nov 03, 2025 pp. 6891-6891 10.1182/blood-2025-6891

Abstract Communication between leukemic cells and the bone marrow microenvironment is thought to play a pivotal role in acute lymphoblastic...

Clinical management of congenital thrombotic thrombocytopenic purpura in Latin America: Expert consensus from a modified Delphi panel

Fernanda Orsi, Hyoung Jin Kang, Jerzy Windyga et al. Nov 03, 2025 pp. 4383-4383 10.1182/blood-2025-4383

Abstract Background Congenital thrombotic thrombocytopenic purpura (cTTP), also referred to as Upshaw-Schulman syndrome or hereditary TTP (h...

Novel trajectory-informed mendelian randomization demonstrates consistent causal protective effect of fetal hemoglobin on clinical outcomes in children with sickle cell disease

Chengzhou Wu, Clifford Takemoto, Kumar Srivastava et al. Nov 03, 2025 pp. 2934-2934 10.1182/blood-2025-2934

Abstract Introduction: Fetal hemoglobin (HbF) plays a critical role in modulating the clinical severity of sickle cell disease (SCD). Severa...

US cost consequence and time toxicity model for advanced therapies in the treatment for Relapsed/Refractory third-line or later diffuse large B-cell lymphoma: A comparison of axicabtagene ciloleucel with bispecific antibodies

Olalekan Oluwole, Jennifer Benner, Madhu Palivela et al. Nov 03, 2025 pp. 6194-6194 10.1182/blood-2025-6194

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most frequently diagnosed lymphoma and often cured in first- or second-lin...

Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial

Arnon Kater, Ann Janssens, Herbert Eradat et al. Nov 03, 2025 pp. 1017-1017 10.1182/blood-2025-1017

Abstract Introduction: RT is a rare, often fatal, transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, mostly d...

Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma

Stephen Smith, Suchitra Sundaram, Sharmila Giri et al. Nov 03, 2025 pp. 3575-3575 10.1182/blood-2025-3575

Abstract Introduction: First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained...

Thrombopoietin receptor agonists combined with intensive immunosuppressive therapy improve outcomes in elderly patients with severe aplastic anemia: A single-center retrospective study

Jinsong JIA, Bo Shao, Xiaofei Jia et al. Nov 03, 2025 pp. 1119-1119 10.1182/blood-2025-1119

Abstract Introduction: Intensive immunosuppressive therapy (IST) has significantly improved the prognosis of elderly patients with severe ap...

Socio-economic deprivation in paediatric patients with B cell -acute lymphoblastic leukaemia : A possible modifiable risk factor based on the real world data from a retrospective survival analysis from the national registry in England

Sandheeah Ramdeny Nov 03, 2025 pp. 2714-2714 10.1182/blood-2025-2714

Abstract Introduction One of the leading reasons for the improved survival rate of paediatric ALL has been the main use of risk-stratified t...

CAR T cells converge on a distinct transcriptional state over time in patients with diverse hematologic malignancies

Xiaoli Mi, Dennis Yuan, Nicholas Midler et al. Nov 03, 2025 pp. 499-499 10.1182/blood-2025-499

Abstract Chimeric antigen receptor (CAR) T cells directed to cancer cells act as a living drug in patients and have the potential to induce...

FAST4TMA: A national rapid ADAMTS13 testing initiative for TMA patients — 2025 update

Clare Martin, Ara Metjian Nov 03, 2025 pp. 600-600 10.1182/blood-2025-600

Abstract Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy (TMA) driven by ADAM...

Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study.

Barbara Duplaix, Anne Lazareth, Maryam Idlhaj et al. Nov 03, 2025 pp. 7530-7530 10.1182/blood-2025-7530

Abstract Background Carfilzomib (K), a next-generation proteasome inhibitor, has proven strong efficacy in Multiple Myeloma (MM), and has de...

Minimal residual disease-guided venetoclax plus rituximab for patients with previously untreated chronic lymphocytic leukemia (VERITA PALG-CLL5): primary endpoint analysis of the prospective, multicenter, Phase 2 trial

Krzysztof Jamroziak, Elzbieta Iskierka-Jazdzewska, Tadeusz Robak et al. Nov 03, 2025 pp. 5675-5675 10.1182/blood-2025-5675

Abstract Background: Fixed-duration regimens combining the selective BCL-2 antagonist venetoclax with an anti-CD20 antibody are currently th...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page